1.Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in antenatal surveillance, diagnosis, and management. Am J Obstet Gynecol. 2011;204(4):288–300.
2.Figueras F, Oros D, Cruz-Martinez R, Padilla N, Haernandez-Andrade E, Botet F, et al., editors. Neurobehavior in term, small-for-gestational age infants with normal placental function. peds; 2009.
3.Illa M, Coloma JL, Eixarch E, Meler E, Iraola A, Gardosi J, et al. Growth deficit in term small-for-gestational fetuses with normal umbilical artery Doppler is associated with adverse outcome. 2009;37(1):48–52.
4.Savchev S, Figueras F, Cruz‐Martinez R, Illa M, Botet F, Gratacos EJUiO, et al. Estimated weight centile as a predictor of perinatal outcome in small‐for‐gestational‐age pregnancies with normal fetal and maternal Doppler indices. 2012;39(3):299–303.
5.Comas M, Crispi F, Cruz-Martinez R, Figueras F, Gratacos EJAjoo, gynecology. Tissue Doppler echocardiographic markers of cardiac dysfunction in small-for-gestational age fetuses. 2011;205(1):57. e1-. e6.
6.Eixarch E, Meler E, Iraola A, Illa M, Crispi F, Hernandez‐Andrade E, et al. Neurodevelopmental outcome in 2‐year‐old infants who were small‐for‐gestational age term fetuses with cerebral blood flow redistribution. 2008;32(7):894–9.
7.Crispi F, Bijnens B, Figueras F, Bartrons J, Eixarch E, Le Noble F, et al. Fetal growth restriction results in remodeled and less efficient hearts in children. 2010.
8.Crispi F, Figueras F, Cruz-Lemini M, Bartrons J, Bijnens B, Gratacos EJAjoo, et al. Cardiovascular programming in children born small for gestational age and relationship with prenatal signs of severity. 2012;207(2):121. e1-. e9.
9.Barker DJ, Osmond C, Winter P, Margetts B, Simmonds SJJTL. Weight in infancy and death from ischaemic heart disease. 1989;334(8663):577–80.
10.Agrawal S, Cerdeira AS, Redman C, Vatish M. Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase–1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study. Hypertension. 2018;71(2):306–16.
11.Zhang J, Merialdi M, Platt LD, Kramer MS. Defining normal and abnormal fetal growth: promises and challenges. Am J Obstet Gynecol. 2010;202(6):522–8.
12.Ananth CV, Vintzileos AM. Distinguishing pathological from constitutional small for gestational age births in population-based studies. Early Hum Dev. 2009;85(10):653–8.
13.Xu H, Simonet F, Luo ZC. Optimal birth weight percentile cut-offs in defining small- or large-for-gestational-age. Acta Paediatr. 2010;99(4):550–5.
14.Galan HL. Timing delivery of the growth-restricted fetus. Semin Perinatol. 2011;35(5):262–9.
15.von Beckerath AK, Kollmann M, Rotky-Fast C, Karpf E, Lang U, Klaritsch P. Perinatal complications and long-term neurodevelopmental outcome of infants with intrauterine growth restriction. Am J Obstet Gynecol. 2013;208(2):130 e1–6.
16.Ridder A, Giorgione V, Khalil A, Thilaganathan B. Preeclampsia: The Relationship between Uterine Artery Blood Flow and Trophoblast Function. Int J Mol Sci. 2019;20(13).
17.Figueras F, Eixarch E, Gratacos E, Gardosi J. Predictiveness of antenatal umbilical artery Doppler for adverse pregnancy outcome in small-for-gestational-age babies according to customised birthweight centiles: population-based study. BJOG. 2008;115(5):590–4.
18.Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J, Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res. 2010;33(9):892–8.
19.Garovic VD. The role of angiogenic factors in the prediction and diagnosis of preeclampsia superimposed on chronic hypertension. Hypertension. 2012;59(3):555–7.
20.Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Serum PLGF as a potential biomarker for predicting the onset of preeclampsia. Arch Gynecol Obstet. 2012;285(2):417–22.
21.Hagmann H, Thadhani R, Benzing T, Karumanchi SA, Stepan H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem. 2012;58(5):837–45.
22.Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond). 2012;122(2):43–52.
23.Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209(6):544 e1- e12.
24.Chaiworapongsa T, Romero R, Whitten AE, Korzeniewski SJ, Chaemsaithong P, Hernandez-Andrade E, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med. 2016;29(8):1214–28.
25.Herraiz I, Droge LA, Gomez-Montes E, Henrich W, Galindo A, Verlohren S. Characterization of the soluble fms-like tyrosine kinase–1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol. 2014;124(2 Pt 1):265–73.
26.Poon L, Akolekar R, Lachmann R, Beta J, Nicolaides KJUiO, Gynecology. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks. 2010;35(6):662–70.
27.Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther. 2011;29(2):148–54.
28.Kirkegaard I, Henriksen TB, Uldbjerg N. Early fetal growth, PAPP-A and free beta-hCG in relation to risk of delivering a small-for-gestational age infant. Ultrasound Obstet Gynecol. 2011;37(3):341–7.